151 related articles for article (PubMed ID: 34802560)
1. Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.
Plaisier E; Not A; Buob D; Ronco P; Debiec H
Kidney Int; 2021 Dec; 100(6):1342-1344. PubMed ID: 34802560
[No Abstract] [Full Text] [Related]
2. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
Brenchley PE
J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
[No Abstract] [Full Text] [Related]
3. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P
Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419
[No Abstract] [Full Text] [Related]
4. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
6. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
7. Rituximab bioavailability in primary membranous nephropathy.
Boyer-Suavet S; Andreani M; Cremoni M; Brglez V; Benzaken S; Bernard G; Nachman P; Esnault V; Seitz-Polski B
Nephrol Dial Transplant; 2019 Aug; 34(8):1423-1425. PubMed ID: 30929012
[No Abstract] [Full Text] [Related]
8. Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy.
Teisseyre M; Brglez V; Cremoni M; Fernandez C; Graça D; Boyer-Suavet S; Benzaken S; Esnault VLM; Seitz-Polski B
Clin J Am Soc Nephrol; 2023 Jun; 18(6):785-787. PubMed ID: 36942995
[No Abstract] [Full Text] [Related]
9. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
[No Abstract] [Full Text] [Related]
10. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
Zhou XJ; Zhou FD; Wang SX; Zhao MH
Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.
Seitz-Polski B; Dahan K; Debiec H; Rousseau A; Andreani M; Zaghrini C; Ticchioni M; Rosenthal A; Benzaken S; Bernard G; Lambeau G; Ronco P; Esnault VLM
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1173-1182. PubMed ID: 31340979
[TBL] [Abstract][Full Text] [Related]
12. [Update membranous nephropathy].
Hoxha E; Huber TB
Dtsch Med Wochenschr; 2020 Oct; 145(20):1481-1485. PubMed ID: 33022730
[TBL] [Abstract][Full Text] [Related]
13. Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
Delafosse M; Ponlot E; Esteve E; Ghislain L; Hanset N; Boffa JJ; Johanet C; Dahan K
Kidney Int; 2021 Apr; 99(4):1023-1024. PubMed ID: 33745532
[No Abstract] [Full Text] [Related]
14. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
Guerry MJ; Vanhille P; Ronco P; Debiec H
Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
[No Abstract] [Full Text] [Related]
16. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation.
Anjum N; Nabi Z
J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554
[TBL] [Abstract][Full Text] [Related]
17. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
18. Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report.
Zhang F; Yang Y; Chen Y; Chen Y; Yin W; Liang Y; Luo X
Medicine (Baltimore); 2022 Sep; 101(37):e30663. PubMed ID: 36123923
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
[TBL] [Abstract][Full Text] [Related]
20. Membranous nephropathy: setting the bar for hypothesis-driven, selective therapies in nephrology.
Angeletti A; Leventhal JS; Cravedi P
J Nephrol; 2021 Apr; 34(2):561-563. PubMed ID: 32683657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
